8-K: Passage Bio Reports Positive Clinical Trial Progress and Strategic Out-Licensing

Passage Bio announced positive progress in its upliFT-D trial, strategic out-licensing of pediatric programs, and a strong cash position extending operations into Q2 2026.

Summary

• Passage Bio reported its second quarter 2024 financial results and provided business updates, highlighting progress in its upliFT-D trial for Frontotemporal Dementia (FTD).
• The company enrolled the first patient in Cohort 2 of the upliFT-D trial for FTD-GRN, following a positive review of Cohort 1 safety data by the IDMC.
• Passage Bio plans to present updated safety and biomarker data from Cohort 1 patients at the International Conference on Frontotemporal Dementias in September 2024.
• The FDA has agreed with Passage Bio's plan to expand the upliFT-D trial to include FTD patients with C9orf72 gene mutations, with dosing expected to begin in the first half of 2025.
• The company completed the out-licensing of its pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, receiving an initial payment of $10 million and potential future payments.
• Passage Bio's cash, cash equivalents, and marketable securities totaled $91.8 million as of June 30, 2024, and the company expects this, along with initial payments from the out-licensing agreement, to fund operations through the end of Q2 2026.
• Research and development expenses were $10.4 million for the quarter ended June 30, 2024, compared to $17.3 million for the same period in 2023.
• General and administrative expenses were $6.5 million for the quarter ended June 30, 2024, compared to $8.1 million for the same period in 2023.
• The net loss for the quarter ended June 30, 2024, was $16.0 million, or $0.26 per share, compared to a net loss of $23.9 million, or $0.44 per share, for the same period in 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the clinical trial progress, FDA agreement, strategic out-licensing, and extended cash runway. The reduction in expenses and net loss also contribute to the positive outlook.

Positives

• The upliFT-D trial is progressing with the enrollment of the first patient in Cohort 2.
• The FDA's agreement to expand the trial to include FTD-C9orf72 patients is a positive development.
• The out-licensing of pediatric programs provides immediate cash and potential future revenue.
• The company has a strong cash position that is expected to fund operations through Q2 2026.
• R&D and G&A expenses have decreased year-over-year.
• The net loss has decreased year-over-year.

Negatives

• The company reported a net loss of $16.0 million for the quarter ended June 30, 2024.
• Cash reserves have decreased from $151.5 million in June 2023 to $91.8 million in June 2024.

Risks

• The company's ability to develop and obtain regulatory approval for its product candidates is subject to risk.
• Clinical trials may not produce the desired results, and regulatory authorities may require additional information or studies.
• The company is dependent on collaborators and third parties for development and manufacturing.
• There are risks associated with potential delays, work stoppages, or supply chain disruptions.
• The company's intellectual property may not be adequately protected or enforced.

Future Outlook

Passage Bio expects to continue advancing its clinical programs, including the upliFT-D trial, and to seek regulatory feedback on the pathway to treating ALS patients. The company anticipates initiating dosing of FTD-C9orf72 patients in the first half of 2025 and has a cash runway to the end of Q2 2026.

Management Comments

• Will Chou, M.D., president and chief executive officer of Passage Bio, stated that this has been a pivotal quarter for the company, marked by significant momentum in the upliFT-D trial.
• Dr. Chou also highlighted increased clarity around the strategy to expand PBFT02 into additional adult neurodegenerative indications and the out-licensing of pediatric lysosomal storage disorder programs.
• Dr. Chou mentioned the positive recommendation of the IDMC to proceed to Cohort 2 dosing in the upliFT-D trial for FTD-GRN, reinforcing the well-tolerated safety profile of PBFT02.
• Dr. Chou expressed excitement about presenting updated safety and biomarker data from Cohort 1 at the ISFTD2024 conference in Amsterdam this September.
• Dr. Chou noted the FDA's alignment with the proposed expansion of the upliFT-D trial to include FTD-C9orf72 patients and expects to initiate dosing of these patients in the first half of 2025.
• Dr. Chou stated that the company remains on track to gain regulatory feedback on the pathway to treating ALS patients with PBFT02 in the second half of 2024.

Industry Context

This announcement reflects the ongoing efforts in the gene therapy space to develop treatments for neurodegenerative diseases. The out-licensing of pediatric programs is a common strategy for biotech companies to focus on core assets while generating revenue. The expansion of the FTD trial to include C9orf72 patients aligns with the industry's focus on addressing genetic subtypes of diseases.

Comparison to Industry Standards

• Passage Bio's approach of using AAV1 for gene delivery is consistent with industry trends in gene therapy, where AAV vectors are commonly used for their safety and efficacy.
• The company's focus on progranulin as a therapeutic target aligns with research in neurodegenerative diseases, where progranulin deficiency is implicated in FTD and other conditions.
• The reported cash runway to Q2 2026 is a positive sign for investors, as it provides financial stability for the company's ongoing clinical programs.
• The out-licensing deal with GEMMA Biotherapeutics is similar to other strategic partnerships in the biotech industry, where companies collaborate to develop and commercialize therapies.
• The reduction in R&D and G&A expenses is a positive sign of cost management, which is important for biotech companies in the clinical stage.

Stakeholder Impact

• Shareholders will likely view the clinical trial progress and extended cash runway positively.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with FTD and other neurodegenerative diseases may have increased hope for new treatment options.
• The out-licensing of pediatric programs may benefit patients with lysosomal storage diseases through GEMMA Biotherapeutics.
• The company's suppliers and partners may see continued business opportunities.

Next Steps

• Passage Bio will present updated safety and biomarker data from Cohort 1 patients at ISFTD2024 in September 2024.
• The company will report 12-month Cohort 1 and interim Cohort 2 data in the first half of 2025.
• Passage Bio will seek regulatory feedback on pivotal trial design in the second half of 2025.
• The company will obtain regulatory feedback on the pathway to treating ALS patients with PBFT02 in the second half of 2024.
• Passage Bio will initiate dosing of FTD-C9orf72 patients in the first half of 2025.

Key Dates

Keywords

Passage Bio, PBFT02, Frontotemporal Dementia, FTD-GRN, FTD-C9orf72, Gene Therapy, Clinical Trial, Neurodegenerative Diseases, Progranulin, GEMMA Biotherapeutics, Out-licensing, Financial Results